---

title: "Peripheral Levels of Selected Biomarkers in Patients with Post-Sarcoidosis Chronic Fatigue Syndrome"
tags:
- ‚ûï 2025-12-25
- üß™ Biomarker
created: '2025-12-02'
published: '2025-12-02'

---


<details>
<summary>Ma≈Çuj≈Ço-Balcerska et al. (2025)</summary>

- **Authors:** El≈ºbieta Ma≈Çuj≈Ço-Balcerska, Karol BƒÖczek, Witold G√≥rski, Anna Kumor-Kisielewska, ≈Åukasz Gwadera, Adam Jerzy Bia≈Ças, Wojciech Jerzy Piotrowski.
- **Institutes:** Department of Pneumology, Medical University of ≈Å√≥d≈∫, ≈Å√≥d≈∫, Poland.
- **Publisher:** Journal of Inflammation Research (Dove Medical Press).
- **Link:** [DOI](https://doi.org/10.2147/JIR.S549445)

</details>


## Summary

This research identifies a measurable biological link between persistent fatigue and the immune system in patients who have technically "recovered" from sarcoidosis. By demonstrating that markers like IL-6 and hsCRP remain elevated in fatigued patients, the study provides a potential explanation for why symptoms persist after the primary disease is in remission. This aligns the pathology of post-sarcoidosis fatigue with other chronic fatigue conditions like ME/CFS and Long COVID, suggesting that low-grade inflammation is a shared driver. For patients, these results offer validation that their symptoms have an organic, measurable basis, though further clinical trials are needed before these markers can be used to guide specific treatment protocols.

## What was researched?

This study investigated whether the persistent fatigue and depressive symptoms experienced by sarcoidosis patients in remission are linked to lingering systemic inflammation or oxidative stress. The researchers sought to identify specific peripheral biomarkers that could distinguish between patients who recover fully and those who develop a post-sarcoidosis chronic fatigue syndrome.

## Why was it researched?

Sarcoidosis is an inflammatory disease that often leaves patients with debilitating fatigue (affecting up to 70% of individuals) even after the primary condition has entered remission. The biological mechanisms behind this persistent exhaustion are poorly understood, making it difficult to diagnose or treat. Researchers hypothesized that shared inflammatory pathways‚Äîsimilar to those seen in ME/CFS and Long COVID‚Äîmight be responsible for these ongoing symptoms.

## How was it researched?

This was a comparative cross-sectional study involving 71 patients with sarcoidosis. The participants were divided into three groups: those in remission with significant fatigue (RS/CFS), those in remission without fatigue (R/S), and those with active disease (A/S). The team used validated scales (FAS, BDI, and PHQ-9) to assess fatigue, depression, and quality of life, alongside pulmonary function tests. Blood samples were analyzed via ELISA to measure levels of high-sensitivity C-reactive protein (hsCRP), Interleukin-6 (IL-6), TNF-Œ±, and markers of oxidative stress such as total antioxidant status and 8-isoprostanes.

## What has been found?

The study found that patients suffering from fatigue (both in the active and remission groups) had significantly higher blood levels of hsCRP and IL-6 compared to those in remission without fatigue. Specifically, IL-6 levels were found to correlate moderately with the severity of both fatigue and depressive symptoms. Conversely, no significant differences were found in TNF-Œ± levels or oxidative stress markers between the groups. While lung function was slightly reduced in fatigued patients, it only weakly explained the mental aspects of their fatigue, suggesting the symptoms are driven more by biochemical factors than physical lung capacity.

## Discussion

The authors discuss how these findings support the "low-grade inflammation" hypothesis, where residual immune activity continues to affect the central nervous system even after the main granulomatous disease is controlled. They note that the correlation between IL-6 and mood symptoms suggests a common immune-metabolic pathway for both fatigue and depression in this population. A potential limitation mentioned is the need for larger, more diverse cohorts to confirm these biomarkers across different stages of the disease.

## Conclusion & Future Work

The authors conclude that low-grade systemic inflammation, specifically involving elevated hsCRP and IL-6, plays a key role in the persistence of fatigue during sarcoidosis remission. They suggest that IL-6 could serve as a valuable biomarker for identifying and monitoring this condition. Future research should focus on integrating these inflammatory findings with metabolic and neuroendocrine data to develop targeted interventions for patients.
